Problem

Aeon addresses a gap in conventional, largely reactive healthcare: people can feel healthy while serious disease risks remain undiscovered, yet obtaining a comprehensive assessment typically requires fragmented appointments, tests, and providers. Its core use case is a proactive, single-visit check-up for someone who wants to identify cancer, cardiovascular, neurological, or other risks earlier, when treatment may be more effective and less invasive. The service is positioned as premium healthcare, priced from CHF 2,490 to CHF 6,990, although participating insurers can reimburse up to roughly 75–80% depending on the policy.

Product / Service

Aeon is a Swiss preventive-health platform combining a whole-body MRI, blood biomarkers, and—at higher tiers—genetic testing, body-composition analysis, and AI-assisted interpretation. The MRI takes less than an hour without radiation or contrast; results are delivered through Aeon’s portal as an integrated, understandable report, followed by a video consultation with a radiologist or physician and continued support through its medical network. The benefit is a consolidated risk profile and practical next steps rather than disconnected test results.

Market

Aeon competes in preventive healthcare, consumer diagnostics, longevity, and whole-body medical-imaging services. Its closest comparables include Prenuvo, which also combines whole-body MRI, blood testing, and personalized results reviews, and Germany’s ALTA Klinik, which sells preventive whole-body MRI screening. Aeon differentiates itself through multimodal data integration, AI-supported risk prediction, physician review, and its effort to make the service reimbursable through health-insurance partnerships.

Aeon is an operating, commercial company rather than merely a pre-launch concept: it has publicly bookable and priced packages, launched in 2024, reported more than 1,000 MRI scans by November 2025, and raised approximately €8.2 million, or CHF 7.5 million, in seed funding led by Concentric. It had signed agreements with major Swiss insurers, planned more than 10 additional locations, and later acquired preventive-health startup Holsain, but the reviewed sources do not disclose revenue or a definitive customer count.